# PROCEDYTE: Depocyte® Administration (Liposomal Cytarabine) as Prophylaxis of Neuromeningeal Infiltration in Acute Lymphoblastic Leukemia

> **NCT00944008** · PHASE3 · TERMINATED · sponsor: **PETHEMA Foundation** · enrollment: 7 (actual)

## Conditions studied

- Acute Lymphoblastic Leukemia

## Interventions

- **DRUG:** DepoCyte

## Key facts

- **NCT ID:** NCT00944008
- **Lead sponsor:** PETHEMA Foundation
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-09
- **Primary completion:** 2012-07
- **Final completion:** 2012-07
- **Target enrollment:** 7 (ACTUAL)
- **Last updated:** 2015-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00944008

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00944008, "PROCEDYTE: Depocyte® Administration (Liposomal Cytarabine) as Prophylaxis of Neuromeningeal Infiltration in Acute Lymphoblastic Leukemia". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00944008. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*